Cinven looks to take Synlab private as Covid boost falters

Frankfurt-listed Synlab could be about to be taken private following a non-binding full takeover offer earlier this week. With its full year results released yesterday and facing questions about its plans, HBI asks market experts what they think of the move.

Affidea deal – underbidders and EBITDA

HBI hears that the surprise buyer of European imaging and cancer treatment provider Affidea, Groupe Bruxelles Lambert (GBL) may not have been the highest bidder, despite winning out. HBI considers who else was in the running, and the EBITDA figure that may have been used for the deal.

Affidea bought by Groupe Bruxelles Lambert

Groupe Bruxelles Lambert (“GBL”) has signed definitive agreements to acquire a majority stake in European imaging and cancer treatment provider Affidea from B-FLEXION, the private investment firm of the Switzerland-based billionaire Bertarelli family. GBL will invest up to €1bn of equity for the transaction which is its first substantive healthcare investment.

Will record results for Synlab precipitate Cinven sale?

Almost a year after its IPO, lab giant Synlab has posted strong FY21 results bolstered by Covid, but not, it says, dependant on it. Management say extra cash will be used as a springboard for growth. Could it also lead to private equity majority shareholder Cinven selling its remaining interest?

Affidea sale – potential price and buyers

European imaging and cancer treatment provider Affidea is for sale according to multiple sources. HBI chats to an operator source to find about more about the sale and to speculate on price and purchasers.

How Affidea is driving 10% MRI scan growth

European imaging provider Affidea sees 10% volume growth on MRI scans where it has deployed a programme to track how and when machines are used with proprietary software. Senior VP regional COO Zisis Sotiriou talks to HBI about how it has optimised clinical protocols, identified efficiency savings and gained an extra €2m revenue a year.

Interview: Maris Revalds, Chairman, Health Center 4

Anyone paying attention to the Baltic healthcare market - and at just six million people you'd be forgiven for not - will have noticed an aggressive consolidation of the sector by pharmacy chain & wholesaler, Repharm; something rarely seen elsewhere. Health Center 4 (Veselības centrs 4) is the second-largest to it in Latvia and chairman Revalds speaks on his competitor's moves while also giving us an overview of his business and the local market.

Find Us